4 thousand people applied for the coronavirus vaccine test in Germany
In Germany, 4,000 volunteer subjects applied for the coronavirus vaccine test. A researcher who made a statement about the subject said, “We are in luxury. Normally, we have to look for subjects. ” It is planned that the vaccine given to 50 people will be tested on 168 people in total.
Approximately 4,000 people applied as volunteers to participate in the clinical trials of the coronavirus vaccine administered by the University of Medicine, Tübingen University in Germany.
Research manager Dr.Peter Kremsner told the German news agency DPA: “We are in a luxury that we have never encountered in any clinical trial before. We normally have to look for subjects.”
The vaccine, which has been given to about 50 people, is planned to be tried on 168 people in total. The vaccine trial will be conducted in Tübingen, Hannover, and Munich, as well as in Ghent, Belgium. If positive results are obtained in “first stage” studies, the studies will be carried out with more people.
STARTED IN JUNE
The clinical study at Tübingen University started in mid-June. Within the scope of the study, it is investigated whether the vaccine developed by the German biotechnology company CureVac can be tolerated by humans.
“EVERYTHING’S FINE SO FAR”
According to information reported by research manager Peter Kremsner, no side effects have been observed yet. Stating that “everything is fine until now,” Kremsner underlined that there is no question of any positive or negative shocking discoveries.
Kremsner said in the statement he made in mid-June following the initiation of clinical tests, that the first results could be obtained within two months.
In the studies, the vaccine called “mRNA” is used. mRNA is a kind of messenger molecule that plays a role in the protein production process of the human body.
The CureVac firm came up with claims that US President Donald Trump wanted to buy the rights to the vaccine developed by the firm. The incident caused tensions between Germany and the United States, German Economy Minister Peter Altmaier said, “Germany is not for sale.” Later, the German government became a shareholder to CureVac.